Difference between revisions of "Team:uOttawa/Description"

(Prototype team page)
 
Line 1: Line 1:
 
{{uOttawa}}
 
{{uOttawa}}
 +
{{uo2015-nav}}
 
<html>
 
<html>
 +
<div class="uowrapper">
 +
        <div class="uomenu">
 +
           
 +
        </div>
 +
        <div class="uocontent">
 +
            <h1>Improvement</h1>
 +
            <p>Our biobrick, <a href="http://parts.igem.org/Part:BBa_K1652000">pPGK1Gx</a>, is an improvement to <a href="http://parts.igem.org/Part:BBa_K1400000">pTRE(4)Gx</a> and <a href="http://parts.igem.org/Part:BBa_K1400001">pTRE(2)Gx</a> from uOttawa's 2014 project. While the previous parts were GEV-repressible but required rtTA to express, pPGK1Gx has strong, constitutive expression. This part does not require the cell to have rtTA to get a signal, and does not require the user to maintain a steady concentration of anhydrotetracycline or doxycycline to modulate the rtTA activity. This way, rtTA is free to be used as a transcription factor elsewhere in a genetic network.</p>
 +
            <p>Not only does this behaviour fit with achieving tri-stability, but it is also ideal for implementing new logic gates with genes. This promoter, being repressible, can be used as a single-input NOT gate with a twist. Its input may be able to induce a <i>positive</i> signal somewhere else.</p>
 +
        </div>
 +
    </div>
  
−
<h2> Project Description </h2>
+
<!--<h2> Project Description </h2>
  
 
<p>Tell us about your project, describe what moves you and why this is something important for your team.</p>
 
<p>Tell us about your project, describe what moves you and why this is something important for your team.</p>
Line 43: Line 54:
 
</ul>
 
</ul>
  
−
</div>
+
</div>-->
 
</html>
 
</html>

Revision as of 02:04, 19 September 2015

Improvement

Our biobrick, pPGK1Gx, is an improvement to pTRE(4)Gx and pTRE(2)Gx from uOttawa's 2014 project. While the previous parts were GEV-repressible but required rtTA to express, pPGK1Gx has strong, constitutive expression. This part does not require the cell to have rtTA to get a signal, and does not require the user to maintain a steady concentration of anhydrotetracycline or doxycycline to modulate the rtTA activity. This way, rtTA is free to be used as a transcription factor elsewhere in a genetic network.

Not only does this behaviour fit with achieving tri-stability, but it is also ideal for implementing new logic gates with genes. This promoter, being repressible, can be used as a single-input NOT gate with a twist. Its input may be able to induce a positive signal somewhere else.